News

New Triad Defines Distal Symmetrical Polyneuropathy : The combined case definition should be particularly useful for clinical and epidemiologic research design.


 

The combination of neuropathic signs, symptoms, and abnormal electrodiagnostic studies provides the most accurate diagnosis of distal symmetrical polyneuropathy, according to the authors of a new case definition for the noninflammatory nerve disease.

Considered independently, none of the triad offers perfect diagnostic accuracy in predicting the presence of the peripheral nervous system problem, wrote John D. England, M.D., and colleagues in the multidisciplinary Polyneuropathy Task Force. Yet various combinations of the three alter the degree of diagnostic certainty, which, for polyneuropathy, follows a continuum of probability, the authors stated (Neurology 2005;64:199–207).

The task force, comprising physician representatives from the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation, conducted a systematic literature review of prospective cohort surveys and case review studies. To determine the accuracy of the diagnostic predictors identified through the review, the panel calculated sensitivities and specificities of each, then rank-ordered, from highest to lowest, the likelihood of a positive diagnosis given various combinations of the predictors. They determined, for example, that the highest likelihood of distal symmetric polyneuropathy occurs with a combination of multiple symptoms, multiple signs, and abnormal electrophysiologic studies. Additionally, when multiple symptoms and signs are present but electrophysiologic findings are not available, the likelihood is downgraded to modest, and when signs are discordant with electrophysiologic findings, the likelihood of a positive diagnosis is further diminished.

The evidence-based recommendations evolved from a treatment guideline into a case definition when the task force found the definition of polyneuropathy was inconsistent across the available studies, hampering comparisons, the authors wrote.

The absence of formal criteria for the diagnosis of distal symmetric polyneuropathy has hindered research, said Dr. England of Deaconess Billings (Mont.) Clinic.

Based on the literature review, data classification, and formal consensus process, the authors reached these conclusions:

▸ Neuropathic symptoms alone have relatively poor diagnostic accuracy in predicting the presence of polyneuropathy. Multiple neuropathic symptoms are more accurate predictors than are single symptoms, and should be weighted as such.

▸ Signs are better predictors than are symptoms, and should be weighted as such.

▸ A single abnormality upon examination is less sensitive than multiple abnormalities; thus, physicians should look for combinations of signs.

▸ Relatively simple examinations have the same diagnostic accuracy as do complex scoring systems.

▸ The high degree of inconsistency among studies describing the accuracy of quantitative sensory testing precludes the inclusion of such testing in the case definition.

These conclusions were gleaned from studies specific to distal symmetric polyneuropathy. Using the evidence-based conclusions as its guide, the task force developed an ordered set of case definitions ranked from highest to lowest based on the likelihood of disease, depending on the presence or absence of specific signs, symptoms, and electrophysiological results. (See chart.)

Symptoms of distal symmetric polyneuropathy begin distally in the feet and may be sensory (numbness, burning, dysesthesias, allodynia, and prickling paresthesias), motor (often weakness in the distal legs), or both. On examination, signs of the condition include abnormalities of primary sensory modalities (pain, touch, hot, cold, vibration, and proprioception), motor system, tendon reflexes (especially depressed or absent ankle jerks), or autonomic system.

With respect to electrodiagnostic evaluations, they are recommended but not required to fulfill the case definition criteria. Of the options, nerve conduction studies (NCS) are the most informative, providing a sensitive measure of the functional status of sensory and motor nerve fibers and therefore adding a higher level of specificity to the diagnosis. For this reason, they should be included in the assessment of polyneuropathy, with the caveat that they are neither sensitive nor specific enough on their own to be exclusive diagnostic criteria, the authors wrote. Because no formal consensus exists regarding the best NCS protocol for diagnosing polyneuropathy, the task force developed recommendations based on electrophysiologic principles that combine the highest sensitivity, specificity, and efficiency for diagnosing distal symmetric polyneuropathy. (See sidebar.)

Quantitative sensory testing is not included as part of the final case definition because the sensitivities and specificities of the psychophysical tests vary considerably, and they have greater inherent variability, making standardization difficult, the authors noted. Also excluded are quantitative autonomic tests, because they are not routinely performed in all medical centers.

One possible limitation to the case definition is the reliance on evidence predominantly related to diabetic peripheral neuropathy, the most common and rigorously studied variety. Some “uncertainty exists with respect to the generalization of the case definition to distal symmetric polyneuropathy associated with other etiologies,” the authors wrote.

The new case definition should be particularly useful for clinical and epidemiologic research design and implementation, the authors wrote. Formalizing the case definition “will ensure greater consistency of case selection,” and will go a long way toward standardizing and facilitating clinical research, Dr. England said.

Pages

Recommended Reading

Acupuncture Nearly Halves Headache Days
MDedge Neurology
Pediatric Migraine Guidelines Decry Lack of Data on Kids
MDedge Neurology
Synthetic Marine Snail Toxin Gets FDA Approval as Intrathecal Analgesic
MDedge Neurology
New Agent Approved for Two Neuropathic Pain Conditions
MDedge Neurology
Nerve Damage Less With Sentinel Node Biopsy
MDedge Neurology
Spinal Triage System Culls Candidates for Surgery
MDedge Neurology
Minimally Invasive Surgery an Option For Patients With Trigeminal Neuralgia
MDedge Neurology
Brain May Modulate Chronic Low Back Pain
MDedge Neurology